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Abstract
Purpose: Chronic myeloid leukemia (CML) treatment has improved significantly in the last decade with the introduction of
tyrosine kinase inhibitors (TKIs), which target BCR/ABL oncoprotein. However, a large proportion of patients develop
resistance to this treatment protocol, with frequent relapse cases. CXCR4 up-regulation in leukemic cells induced by TKIs has
been reported as a mechanism of chemoresistance by promoting migration of these cells to bone marrow, where they receive
pro-survival signals and persist as quiescent cells. In the present study, we investigated the possible influence of treatment on
the expression of CXCR4 and CXCL12 in peripheral blood cells of CML patients. Methods: Relative expressions (RE) were
calculated from mRNA obtained from leukocytes of 21 patients in chronic phase, under treatment, and 54 healthy individuals,
used as controls. Results: CXCR4 expression was increased in CML patients compared to controls (RE: 1.931; p = 0.006). In CML
patients, CXCR4 and CXCL12 expressions were correlated (r = 0.631; p = 0.002), and no differences in the expression of these
genes were observed among different treatment protocols. However, CXCR4 expression was positively correlated with imatinib
treatment period duration of treatment (r = 0.56; p = 0.02). Conclusion: This data has pointed peripheral blood CXCR4
expression as a possible marker for treatment monitoring, which may be useful to predict which patients would be benefit from
newly developed treatments targeting CXCR4 and BCR/ABL concomitantly.
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Introduction
Chronic myeloid leukemia (CML) is a hematological disease
that represents 20% of all adult leukemias, with an annual
incidence of 1-2 cases per 100,000 individuals. This disease
occurs at any age, but peaks of incidence are seen at 5th and 6th
decades of life.1,2 The prevalence of CML is increasing
worldwide, and in 2014 estimates indicated 160,000 people
living with this disease.3
CML is a proliferative disease of the hematopoietic system
characterized by an overproduction of granulocytic lineage
cells, and is associated with translocation between
chromosomes 9 and 22, generating the fusion protein
BCR-ABL.4 This fusion gene results in constitutive activation
of the ABL kinase, whose oncogenic properties include
inhibition of apoptosis, proliferative advantage independent
of growth factors, altered cell-cell and cell-matrix
interactions and leukemogenesis.5
Historically, CML patients were treated with hydroxyurea
and interferon-alpha (IFN-α) alone or in combination with
low-dose cytarabine, and allogeneic stem cell transplantation.
CML treatment changed dramatically in 2001 with the
approval of imatinib, the first BCR-ABL tyrosine kinase
inhibitor (TKI), followed by dasatinib, nilotinib, bosutinib,
and more recently ponatinib.6
Standard treatment of CML with TKIs is highly effective in
reducing disease burden, delaying disease progression, and
prolonging overall survival of patients. However, up to 20%
of CML patients who start on first-line TKI therapy will
develop resistance to treatment which is caused, mainly, by
mutations in the BCR-ABL kinase domain, hampering
TKI-binding sites.7
CXCR4 is a seven-transmembrane G-protein-coupled
chemokine receptor, expressed in hematopoietic and
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epithelial cancer cells 8, and appear to be an essential factor
for survival and chemotherapy resistance in leukemia.
CXCL12, a ligand for CXCR4, is a soluble pro-survival factor
secreted by bone marrow (BM) stromal cells, the primary
component of BM microenvironment.9,10 The binding of
CXCL12 to CXCR4 induces several intracellular signals
related to chemotaxis, homing, cell survival and proliferation,
and is involved in treatment resistance of CML.9
Apart from its role in the pathogenesis of CML,
CXCR4/CXCL12 axis regulates stem/progenitor cell migration
and retention in the marrow, and is required for
hematopoiesis. In 2002, Ptasznik, Urbanowska11
demonstrated for the first time, the existence of a crosstalk
between BCR-ABL and CXCR4 pathways in leukemia cells:
BCR-ABL disrupted chemokine signaling and chemotaxis,
and increased the ability of immature myeloid cells to escape
from BM into circulation. However, studies have shown that
the downregulation of CXCR4 expression could be reversible
by TKIs, such as imatinib, promoting migration of CML cells
to BM stroma, causing cycle arrest and, hence, ensuring the
survival of quiescent CML progenitor cells.12,13
In this context, the present study aimed to investigate the
expression of CXCL12 and CXCR4 in peripheral blood cells of
CML patients and healthy individuals, and the impact of TKI
treatment on their expressions.
Methods and Materials
Study population
Following approval from the Human Ethics Committee of the
State University of Londrina (CAAE n°. 0164.0.268.000-09) 5
mL of peripheral blood were obtained from 21 patients with
clinical and hematological diagnosis for CML, in the chronic
phase and under treatment at the time of sampling. All
patients and healthy individuals (n = 54) were attended in the
Cancer Hospital of Londrina and University Hospital of State
University of Londrina, Londrina-PR, Brazil, and have signed
a term of free informed consent.
RNA extraction and cDNA synthesis
Leukocytes were prepared from peripheral blood samples
using red blood cells (RBC) lysis buffer (SigmaAldrich). Total
cellular RNA was obtained from these cells submitted to
TRIzol LS reagent extraction (Invitrogen™, Carlsbad, U.S.A.)
according to the manufacturer’s instructions. RNA
concentration was determined spectrophotometrically at 260
and 280 nm, andstored at -20º C until use. Reverse
transcription reaction (RT) was performed using 500 ng of
RNA, 20 units of cloned moloney murine leukemia virus
reverse transcriptase (M-MLV RT; Invitrogen™) and 4 units
of recombinant ribonuclease inhibitor (RNaseOUT™;
Invitrogen™), under the following conditions: 2.5 μM oligo
dT, 50 mM Tris HCl pH 8.3, 75mM KCl, 1.5 mM MgCl2, 1.25
mM of dNTP, at 42º C for 60 min in Hybaid PCR Sprint
Thermal Cycler (Biosystems, Guelph, Ontario, Canada).
Molecular analysis of Beta-actin mRNA
PCR for beta-actin amplification was performed with cDNA
to analyze the viability of the RNA samples and cDNA
quality. Briefly, cDNA synthesis was carried as described by
Amarante et al.14, and PCR conditions were: 94ºC for 1 min
followed by 35 cycles at 94ºC for 30 sec, 55ºC for 30 sec, 72ºC
for 1 min and finally, 72ºC for 10 min in Hybaid PCR Sprint
Thermal Cycler (Biosystems, Guelph, Ontario, Canada). The
amplified PCR product consisted of a 353bp fragment,
analyzed in a polyacrylamide gel (10%) electrophoresis. All
the RNA samples presented detectable quantities of
beta-actin mRNA and acceptable integrity during
amplification. No contamination with genomic DNA was
verified.
Quantitative real-time PCR for CXCL12 and CXCR4
mRNA
Real-time PCR using SYBR green fluorescent dye was
performed with 2.0μl cDNA in 20μl total reaction volume.
Each real-time PCR reaction consisted of 2.5μL RT-PCR
product, 10μL Platinum®SYBR Green qPCR SuperMix UDG
(Invitrogen TM) and 0.25μM of each sense and antisense
primer.
For quantitative polymerase chain reaction (qPCR) was used
specific primers: 5’ TTACCCGCA AAAGACAAGT 3’ as sense
and 5’ AGGCAATCACAAAACCCAGT 3’ as antisense
primers for CXCL12, and 5’ TGTTGGCTGAAAAGGTGGTC
3’ as sense and 5’ AAA GATGAAGTCGGGAATAGTC 3’ as
antisense primers for CXCR4. As a housekeeping gene,
human glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was amplified using the sense primer 5’
GAAGGTGAAGGTCGGA 3’ and antisense primer 5’
GGGTCATTGATGGCAAC 3’. The PCR reaction was
performed for 40 cycles as follows: 95°C for 30 sec, 54°C for 30
sec and 72°C for 30 sec in a Chromo4™ Real Time PCR
Detection (Bio-Rad, Hercules, U.S.A.). The qPCR results were
analyzed according to the Pfaffl method.15
Statistical Analysis
Differences for gene expression between CML and control
group were assessed using the relative expression software
tool (REST) 2009. Nonparametric Kruskal-Wallis and
Mann-Whitney U tests were performed to compare CXCL12
and CXCR4 expressions in groups treated with different drugs
(imatinib, nilotinib or other) and different imatinib doses
(400 or 600-800 mg/day). Correlation analyses were
performed using Spearman’s nonparametric test. Data were
analyzed using GraphPad Prism 6.0, with the level of
significance set at p < 0.05.
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Results
Sample characterization
Twenty-one patients with CML under treatment were
included: 15 were treated with imatinib (9 patients with
400mg/day; 5 with 600mg/day and 1 with 800mg/day), 3 with
nilotinib (200mg/day), 2 with dasatinib (70mg/day and
200mg/day) and 1 with hydroxyurea (1g/day).
Median age was 44.50 years (range: 31-80) in CML group and
36.00 years (range: 25-56) in control group. Despite this
difference being statistically significant (p = 0.0004), no
influence of age in the expression of CXC12 or CXCR4 was
detected either in control (p = 0.61, r=0.07 and p = 0.66, r =
-0.06 for CXCL12 and CXCR4, respectively) or in CML group
(p = 0.68, r = 0.09 and p = 0.51, r = 0.14).
CXCR4 but not CXCL12 is differentially expressed in
CML patients
CXCL12 was not differently expressed in CML patients
compared to control group (fold change expression: 0.960; p =
0.82). However, CXCR4 expression was approximately
two-fold higher (RE: 1.80) in patients with CML compared to
controls (p = 0.02). Figure 1 shows the expression distribution
of each CML patient in relation to control group.
FIG. 1: CXCL12 and CXCR4 relative expressions in CML patients.
Individual values were calculated using mean cycle thresholds and
efficiency values as parameters. Lines indicate median expression
value plus interquartile range.
CXCL12 and CXCR4 expressions are correlated in CML
patients, but not in controls
We investigated if there was a correlation between CXCL12
and CXCR4 expression in leukocytes, and our results showed
that these genes were positively correlated in CML (n = 22, p
= 0.002; r = 0.631) but not in control group (n = 54, p = 0.68; r
= 0.06) (Figure 2).
FIG. 2: CXCL12 and CXCR4 expressions are correlated in CML. Correlation analyses between CXCL12 and CXCR4 relative expressions in controls
(A) and CML (B) groups. Data are shown as individual expression values relative to mean control expression. P and rho values were obtained from
Spearman’s correlation tests.
CXCL12 and CXCR4 expressions between different
treatment protocols among CML
Peripheral blood CXCL12 and CXCR4 expressions were
compared between patients receiving imatinib (n = 15),
nilotinib (n = 3) or other treatment (2 patients receiving
dasatinib and 1 receiving hydroxyurea). No significant
differences between these treatment groups were observed
for any of the studied genes (p = 0.972 for CXCL12 and p =
0.542 for CXCR4) (Figure 3A and 3B).
In patients undergoing treatment with imatinib, CXCL12 and
CXCR4 expressions were compared between those receiving
400 mg and 600 – 800 mg of the drug per day. No statistical
differences were observed for the expression of both genes
(CXCL12: p = 0.14; CXCR4: p = 0.17) (Figure 3C and 3D).
These results suggest that the observed increment in CXCR4
expression in CML patients is not dependent on treatment
type or dose.
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FIG. 3: CXCL12 and CXCR4 expressions according to treatment drug and imatinib dose. CXCL12 (A) and CXCR4 (B) relative expressions were
compared between patients receiving different treatment protocols. The group “other” was composed by two patients receiving desatinib and one
receiving hydroxyurea. (C and D): CXCL12 (C) and CXCR4 (D) expression comparison between patients receiving 400 or 600-800mg. Lines
indicate median expression value plus interquartile range.
FIG. 4: CXCL12 and CXCR4 expression in relation to the treatment time in CML patients. Correlation analyses between
expressions of CXCL12 (A) and CXCR4 (B) and treatment duration. P and rho values were obtained from Spearman’s correlation
tests.
CXCR4 expression was positively correlated with
treatment time with imatinib
We investigated weather treatment time with TKI influenced
CXCL12 or CXCR4 expression in CML patients. For this
purpose, we performed correlation analyses between
treatment time and either CXCL12 and CXCR4 expressions
only in patients that were being treated with imatinib (n =
15). It was observed a positive correlation between CXCR4
expression and treatment time with imatinib (p = 0.02; r =
0.56) (Figure 4A). No correlation was observed for CXCL12
expression (p = 0.44; r = 0.21) (Figure 4B).
Discussion
CML is a malignant neoplasia of hematopoietic stem cells,
resulting in massive presentation of myeloid lineage cells in
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peripheral blood and excessive myeloid proliferation in the
BM16, usually affecting people over 45 years. In this study,
CML patients had ranged in age from 31 to 80 years (median:
44.5 years), which is in agreement with Cid, Magalhaes17 that
found a median age CML group consisting of 41.5 years.
According to another study realized in 20 European countries
with CML patients, the median age found was 55 years18; but
it is considerably lower in countries where the population is
younger.19
Chemokines and their receptors are involved in the
development of several disorders, including cancer.
Particularly, the chemokine receptor CXCR4 has been
reported to be highly expressed in cancer cells, including
those from hematopoietic origin, and essentially implicated in
leukemia cell survival and drug resistance.20,21 Moreover,
CXCR4/CXCL12 interaction activates several intracellular
signals related to chemotaxis, homing, cell survival and
proliferation.22
Accumulating evidence suggests that leukemia cells are
protected by marrow stromal cells (MSCs) 23 and indirect
communication through CXCL12 and direct contact between
leukemia cells and MSCs have been demonstrated to be
essential for CML cell survival and resistance.24 CXCL12 may
protect CML cells from chemotherapeutic-induced apoptosis,
and activation of CXCR4 induces CML cell homing to the BM
microenvironment.20 Our study demonstrated that CXCR4
expression was higher in peripheral blood of CML patients
when compared to healthy controls and correlates with
CXCL12 expression. These data corroborate with several
studies reporting important involvement of the
CXCR4/CXCL12 axis as a potential target for new therapeutic
strategies in leukemia patients.25,26
CML was the first cancer in which an effective
targeted-therapy has been outlined 27, and once TKIs were
developed, they were proved to be more efficient in
controlling the disease than other types of chemotherapy,
such as IFN-α or hydroxyurea. This therapy targets the
tyrosine kinase BCR/ABL, which is responsible of
leukemogenic events in CML, and the use of these inhibitors
can reverse the malignant changes in the leukemic cells
and/or cause cell apoptosis.28,29
Imatinib is effective in most CML patients, however a
considerable proportion of them, some still in the chronic
phase and a higher proportion in later phases, are resistant or
intolerant to imatinib.30,31 It is known that some patients fail
initial treatment (primary resistance), while others lose a
previously acquired response (secondary resistance); the
latter is the most common and associated with development
of mutations in the BCR/ABL site.32,33 Other tyrosine kinase
inhibitors were developed as second generation drugs, such as
nilotinib and dasatinib34, but they both might induce
resistance.35,36
Several other strategies are in use to improve CML treatment,
including imatinib dose escalation combining different
therapies, initial use of second generation tyrosine kinase
inhibitors and maintaining therapy with IFN-α and vaccine.37
The resistance mechanisms have been analyzed and the most
common is reactivation of kinase activity by BCR/ABL point
mutations or gene amplification.38 A point mutation in the
tyrosine kinase binding site can prevent imatinib coupling by
interrupting critical points of contact, or by inducing a
protein impairment to which the drug cannot associate.39
Depending on the mutation present, dose escalation may be a
good strategy to restore the response to imatinib.
More recently, analysis of gene expression profiles identified
the expression of the chemokine CXCL12 as a sensitivity
predictor to imatinib. Vianello, Villanova10 reported that
leukemic cell survival mechanism in CML mediated by BM
stroma mesenchymal cells is related to protection from
apoptosis induced by imatinib, through CXCR4/CXCL12
activation. In the present study we verified that CXCR4, but
not CXCL12, expression is positively correlated with imatinib
treatment time.
It has been demonstrated that imatinib treatment increased
CXCR4 expression and induced leukemic cell migration to
BM stroma, which promoted survival of quiescent CML cells
during treatment13, making approaches targeting both
BCR-ABL and CXCR4 attractive to more efficiently manage
disease and overcome treatment resistance.
Otherwise, Peled, Hardan 40 demonstrated that CD34+
Philadelphia-positive CML cells expressing CXCR4 migrate
in response to factors derived from BM stroma (particularly,
CXCL12). However, CD34+ CXCR4+, but Philadelphia
negative (normal) cells from the same patient showed higher
rates of migration by CXCL12, indicating a functional role
mediated by CXCL12 in retention of CD34+ immature cells
and progenitor cells in BM of healthy individuals and CML
patients.
Moreover, it was recently shown that CXCR4 overexpression
in the CML cell line K562 does not increase the migratory
potential of CML cells, but rather supports their survival and
growth, therefore confirming the pro survival role of CXCR4
in CML.41
Though, it is reasonable to assume that inhibiting CXCR4
might represent a possible therapeutic strategy in managing
CML patients experiencing drug resistance. In fact, Zeng,
Samudio42 described that CXCR4 inhibition with the novel
RCP168 peptide overcomes stroma-mediated
chemoresistance in chronic and acute leukemias. In the same
way, another high affinity CXCR4 inhibitor, BKT140,
abrogated proliferation and induced significant apoptotic cell
death in CML cells, mainly in combination with imatinib.41
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Similarly, plerixaflor (AMD3100, Genzyme Corporation), a
CXCR4 inhibitor used for cell mobilization from BM to
peripheral blood in hematopoietic stem cell transplantation,
was shown to disrupt the interaction of CML cells with BM,
sensitizing them to nilotinib treatment. Co-administration of
plerixaflor and nilotinib delayed time to relapse and
prolonged survival in a xenograft model of CML in mice.43
Co-inhibition of BCR-ABL and CXCR4 already reached a
phase I clinical trial (identifier NCT02115672 at
https://clinicaltrials.gov website), but are not yet open for
patient recruitment.
Several mechanisms should be considered in treatment
failure with imatinib, and they should be clarified to offer
patient the best second-line treatment, whether dose
optimization, another tyrosine kinase inhibitor or BM
transplantation. In future, multiple treatment options will be
available to CML patients and strategic combinations of new
anticancer drugs, taking into account the patient's condition
and response to different drugs, might prevent the
development of resistant clones.
Finally, time of treatment with imatinib was positively
correlated with CXCR4 relative expression in CML patients,
suggesting that CXCR4 up-regulation by imatinib occurs even
in peripheral blood cells. As these cells are readily accessible,
our results might indicate a feasible way to monitor CXCR4
expression during TKI therapies, which may have a direct
prognostic role indicating which patients are more likely to
develop chemoresistance and which of them might be
benefited by co-treatments with TKI and CXCR4 inhibitors.
Future cohort studies investigating the association between
CXCR4 expression in peripheral blood leukocytes and
relapses or TKI resistance in CML patients will be necessary
to corroborate this analysis as a feasible method for clinical
use in treatment monitoring.
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